Continued Pre-Market Rally For NeuroBo Pharmaceuticals' (NRBO) Stock
Continued Pre-Market Rally For NeuroBo Pharmaceuticals' (NRBO) Stock
The Series A warrants will expire sixty days after the public release of a favorable Phase 1 multiple ascending dose (MAD) data readout for DA-1726, or twelve months after the stockholder approval. The Series B warrants will expire either six months after the Phase 1 Part 3 data readout for DA-1726 is publicly announced or five years after the stockholder approval.As the market begins today, shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) seem to be continuing their prior session's gain, propelled by news of recent and successful stock transactions. The pre-market trading activity for NRBO shares showed a 12.91% increase in value, closing at $4.81.
随着市场今天的开始，NeuroBo Pharmaceuticals，Inc.（纳斯达克：NRBO）的股票在继续前一交易日的涨势，迎来了最近成功的股票交易的资讯推动。NRBO股票的盘前交易活动显示股票价值增加了12.91％，收盘价为$4.81。
Equity Deals And Issues
股权交易和问题
NeuroBo Pharmaceuticals (NRBO) has completed its previously announced private placement, in which 4,325,701 shares of common stock were sold for $3.93 a share. The business concurrently issued and sold 763,359 shares of ordinary stock at the same price through a registered direct offering.
NeuroBo Pharmaceuticals（NRBO）已完成之前宣布的私募股份配售，以每股$3.93的价格出售了4,325,701股普通股。同时业务通过一项注册直接发行以相同价格发行并出售了763,359股普通股。
NeuroBo also issued unregistered Series A and Series B warrants to acquire up to 5,089,060 and 7,633,591 shares of common stock, respectively, in addition to the equity transactions. The exercise price of each set of warrants is $3.93 per share, and they can be exercised only with stockholder permission.
除了股权交易，NeuroBo还发行了未注册的A和B系列认股权，分别可以获得不超过5,089,060股和7,633,591股的普通股。每组认股权的行使价格为每股$3.93，只能在股东许可的情况下行使。
The Series A warrants will expire sixty days after the public release of a favorable Phase 1 multiple ascending dose (MAD) data readout for DA-1726, or twelve months after the stockholder approval. The Series B warrants will expire either six months after the Phase 1 Part 3 data readout for DA-1726 is publicly announced or five years after the stockholder approval.
A系列认股权将在DA-1726获得有利的1期多剂量（MAD）数据披露后60天内到期，或在股东批准后12个月内到期。B系列认股权将在DA-1726的1期第3部分数据披露后6个月内到期，或在股东批准后5年内到期。
Promising Pre-Clinical Data For DA-1726
DA-1726有着良好的预临床数据
Recently, NeuroBo disclosed pre-clinical data indicating that DA-1726 demonstrated superior results in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide in pre-clinical models. This data was presented by Tae-Hyoung Kim, the lead research scientist at Dong-A ST Research Center, at the American Diabetes Association (ADA) 84th Scientific Sessions held from June 21-24 in Orlando, Florida.
最近，NeuroBo披露了预临床数据，表明DA-1726在减轻体重，保留肌肉和降低脂质方面展现了比survodutide更好的效果。此数据由东亚制药股份有限公司研究中心首席研究科学家金泰炯在美国糖尿病学会于6月21日至24日在佛罗里达州奥兰多举行的第84届科学会议上展示。
The presented data highlights that DA-1726 distinguishes itself from other obesity drugs in the same class, likely due to its unique GLP-1 and glucagon receptor activity ratio. In obese mouse models, DA-1726 significantly reduced cholesterol levels and induced superior weight loss compared to survodutide, while also exhibiting better glucose-lowering effects. Notably, DA-1726 showed superior weight loss and preservation of lean body mass compared to survodutide.
展示的数据凸显出DA-1726与同一类别中其他减肥药物的不同之处，可能是由于其独特的GLP-1和胰高血糖素受体活性比。在肥胖的小鼠模型中，DA-1726显著降低了胆固醇水平，比survodutide表现出更好的减重效果，同时也表现出更好的降糖效果。值得注意的是，与survodutide相比，DA-1726显示了更好的减重和保留瘦体组织的效果。